BCR and lymphoma: C-X-C motif chemokine ligand 10 (CXCL10), which is relevant to lymphoma cell survival [59], was significantly downregulated in the tirabrutinib treatment group (fold change 0.068739, P-value = 8.62E-12), whereas arachidonic acid 5-lipoxygenase (ALOX5, fold change 9.19, P-value = 6.94E-14) was upregulated, which suggests BCR signal suppression [60].